Abstract
Aldo-keto reductase 1 member B1 (AKR1B1) is pathogenically involved in diabetic complications by driving glucose flux through polyol pathway; a variety of AKR1B1 inhibitors has been developed for the treatment of diabetic complications and a body of invaluable preclinical and clinical data have been collected through decades efforts. Recent studies have shown that some AKR1B1 inhibitors demonstrate strong inhibitory activity to aldo-keto reductase family 1 member B10 (AKR1B10), a protein identical to AKR1B1, in vitro and in cancer cells. AKR1B1 and AKR1B10 are overexpressed in human tumors, such as liver, breast, and lung cancer, and may play a critical role in the development and progression of cancer through carbonyl detoxification, retinoic acid homeostatic regulation, and lipid metabolic control, as well as the activation of tobacco smoke carcinogens. Therefore, AKR1B1 inhibitors may represent a novel class of antitumor agents; and the clinical data assembled in diabetic clinics would greatly assist the transition of these inhibitors to cancer clinics. This article summaries the current understanding of the expression and function of AKR1B1 and AKR1B10 in human cancers and reviews the patents and papers of AKR1B1 inhibitors. Authors opinions concerning the current and future development of AKR1B1 and/or AKR1B10-specific inhibitors are discussed.
Keywords: Aldose reductase, aldose reductase-like-1, Aldo-keto reductase family 1 B1, Aldo-keto reductase family 1 B10, AR, ARL-1, AKR1B1, AKR1B10, aldose reductase inhibitor, ARI
Recent Patents on Anti-Cancer Drug Discovery
Title: Aldo-Keto Reductase Family 1 Member B1 Inhibitors: Old Drugs with New Perspectives
Volume: 4 Issue: 3
Author(s): Jianghua Liu, Gebo Wen and Deliang Cao
Affiliation:
Keywords: Aldose reductase, aldose reductase-like-1, Aldo-keto reductase family 1 B1, Aldo-keto reductase family 1 B10, AR, ARL-1, AKR1B1, AKR1B10, aldose reductase inhibitor, ARI
Abstract: Aldo-keto reductase 1 member B1 (AKR1B1) is pathogenically involved in diabetic complications by driving glucose flux through polyol pathway; a variety of AKR1B1 inhibitors has been developed for the treatment of diabetic complications and a body of invaluable preclinical and clinical data have been collected through decades efforts. Recent studies have shown that some AKR1B1 inhibitors demonstrate strong inhibitory activity to aldo-keto reductase family 1 member B10 (AKR1B10), a protein identical to AKR1B1, in vitro and in cancer cells. AKR1B1 and AKR1B10 are overexpressed in human tumors, such as liver, breast, and lung cancer, and may play a critical role in the development and progression of cancer through carbonyl detoxification, retinoic acid homeostatic regulation, and lipid metabolic control, as well as the activation of tobacco smoke carcinogens. Therefore, AKR1B1 inhibitors may represent a novel class of antitumor agents; and the clinical data assembled in diabetic clinics would greatly assist the transition of these inhibitors to cancer clinics. This article summaries the current understanding of the expression and function of AKR1B1 and AKR1B10 in human cancers and reviews the patents and papers of AKR1B1 inhibitors. Authors opinions concerning the current and future development of AKR1B1 and/or AKR1B10-specific inhibitors are discussed.
Export Options
About this article
Cite this article as:
Liu Jianghua, Wen Gebo and Cao Deliang, Aldo-Keto Reductase Family 1 Member B1 Inhibitors: Old Drugs with New Perspectives, Recent Patents on Anti-Cancer Drug Discovery 2009; 4 (3) . https://dx.doi.org/10.2174/157489209789206931
DOI https://dx.doi.org/10.2174/157489209789206931 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Biotechnological Engineering of Heparin/Heparan Sulphate: A Novel Area of Multi-Target Drug Discovery
Current Pharmaceutical Design Subject Index To Volume-3
Letters in Drug Design & Discovery Inhibitors of DNA Methyltransferases: Insights from Computational Studies
Current Medicinal Chemistry Decoding the Emerging Patterns Exhibited in Non-coding RNAs Characteristic of Lung Cancer with Regard to Their Clinical Significance
Current Genomics Cancer Stem Cells – Are Surface Markers Alone Sufficient?
Current Stem Cell Research & Therapy Editorial (Thematic Issue: Pulmonary Delivery of Systemic Drugs- from Aerosol Generation to Efficacious Delivery)
Current Pharmaceutical Design Large Porous Hollow Particles: Lightweight Champions of Pulmonary Drug Delivery
Current Pharmaceutical Design Editorial (Hot Topics: Naturally Occurring Molecules and Anticancer Combination Therapies in the Era of Personalized Medicine and Economic Crisis)
Current Pharmaceutical Design Monoclonal Antibodies, Bispecific Antibodies and Antibody-Drug Conjugates in Oncohematology
Recent Patents on Anti-Cancer Drug Discovery Novel Insights Into the Role of MicroRNA in Lung Cancer Resistance to Treatment and Targeted Therapy
Current Cancer Drug Targets Glycosylation of Tetraspanin Tspan-1 at Four Distinct Sites Promotes Its Transition Through the Endoplasmic Reticulum
Protein & Peptide Letters A Novel Quinoline Based Second-generation mTOR Inhibitor that Induces Apoptosis and Disrupts PI3K-Akt-mTOR Signaling in Human Leukemia HL-60 Cells
Anti-Cancer Agents in Medicinal Chemistry Editorial (Thematic Issue: Investigate the Functions of Chemicals Through Heterogeneous Network of Chemicals and Proteins)
Combinatorial Chemistry & High Throughput Screening Editorial [Hot Topic: The Pineal Hormone Melatonin in Health and Disease (Guest Editors: Charanjit Kaur)]
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery A Prooxidant Mechanism for the Anticancer and Chemopreventive Properties of Plant Polyphenols
Current Drug Targets Molecular Targeted Therapies in the Management of Head and Neck Squamous Cell Carcinoma: Recent Developments and Perspectives
Anti-Cancer Agents in Medicinal Chemistry APO2L/TRAIL: New Insights in the Treatment of Autoimmune Disorders
Recent Patents on Inflammation & Allergy Drug Discovery Immunological Aspects of the Prostate Gland and Related Diseases
Current Immunology Reviews (Discontinued) Intracellular Redox State as Target for Anti-Influenza Therapy: Are Antioxidants Always Effective?
Current Topics in Medicinal Chemistry Biological Activity and Delivery of Peptide Nucleic Acids (PNA)-DNA Chimeras for Transcription Factor Decoy (TFD) Pharmacotherapy
Current Medicinal Chemistry